Table 1.
Demographic and Treatment Characteristics for Survivors and Siblings
| Characteristic | Total Cohort |
Age 35 or Older at Last Follow-Up |
||||||
|---|---|---|---|---|---|---|---|---|
| Survivors |
Siblings |
Survivors |
Siblings |
|||||
| No. of Participants (n = 14,359) | % | No. of Participants (n = 4,031) | % | No. of Participants (n = 5,604) | % | No. of Participants (n = 1,969) | % | |
| Sex | ||||||||
| Female | 6,645 | 46.3 | 2,088 | 51.8 | 2,660 | 47.5 | 1,074 | 54.5 |
| Male | 7,714 | 53.7 | 1,943 | 48.2 | 2,944 | 52.5 | 895 | 45.5 |
| Race/ethnicity* | ||||||||
| Non-Hispanic white | 12,397 | 86.6 | 3,509 | 90.4 | 5,063 | 90.6 | 1,768 | 92.8 |
| Hispanic | 749 | 5.2 | 149 | 3.8 | 219 | 3.9 | 55 | 2.9 |
| Non-Hispanic black | 733 | 5.1 | 123 | 3.2 | 192 | 3.4 | 49 | 2.6 |
| Other | 429 | 3.0 | 101 | 2.6 | 114 | 2.0 | 34 | 1.8 |
| Age at last contact, years | ||||||||
| 0-19 | 1,524 | 10.6 | 267 | 6.6 | — | — | — | — |
| 20-29 | 4,493 | 31.3 | 1,136 | 28.2 | — | — | — | — |
| 30-39 | 5,226 | 36.4 | 1,396 | 34.6 | 2,488 | 44.4 | 737 | 37.4 |
| 40-49 | 2,747 | 19.1 | 979 | 24.3 | 2,747 | 49.0 | 979 | 49.7 |
| ≥ 50 | 369 | 2.5 | 253 | 6.3 | 369 | 6.6 | 253 | 12.8 |
| Age at primary diagnosis, years | ||||||||
| 0-4 | 5,754 | 40.1 | — | 686 | 12.2 | |||
| 5-9 | 3,201 | 22.3 | 1,052 | 18.8 | ||||
| 10-14 | 2,913 | 20.3 | 1,887 | 33.7 | ||||
| 15-20 | 2,491 | 17.3 | 1,979 | 35.3 | ||||
| Primary diagnosis | ||||||||
| Acute lymphoblastic leukemia | 4,329 | 30.1 | — | 1,195 | 21.3 | |||
| Acute myeloid leukemia | 356 | 2.5 | 128 | 2.3 | ||||
| Other leukemia | 145 | 1.0 | 46 | 0.8 | ||||
| CNS tumors | 1,876 | 13.1 | 654 | 11.7 | ||||
| Hodgkin lymphoma | 1,927 | 13.4 | 1,341 | 23.9 | ||||
| Non-Hodgkin lymphoma | 1,080 | 7.5 | 557 | 9.9 | ||||
| Kidney tumors | 1,256 | 8.7 | 221 | 3.9 | ||||
| Neuroblastoma | 955 | 6.7 | 120 | 2.1 | ||||
| Soft tissue sarcoma | 1,246 | 8.7 | 579 | 10.3 | ||||
| Bone tumors | 1,189 | 8.3 | 763 | 13.6 | ||||
| Therapy for primary diagnosis | ||||||||
| Surgery* | ||||||||
| Any surgery | 10,234 | 81.3 | 4,368 | 86.5 | ||||
| Nephrectomy | 1,091 | 8.7 | 203 | 4.0 | ||||
| Splenectomy | 1,257 | 10.0 | 915 | 18.1 | ||||
| Surgery only | 909 | 7.3 | 372 | 7.4 | ||||
| Chemotherapy* | ||||||||
| Any chemotherapy | 10,137 | 80.6 | — | 3,813 | 75.5 | |||
| Alkylator | 6,826 | 54.3 | — | 2,749 | 54.4 | |||
| Anthracycline | 5,190 | 41.3 | — | 1,841 | 36.5 | |||
| Bleomycin | 756 | 6.0 | — | 425 | 8.4 | |||
| Cisplatin | 738 | 5.9 | — | 193 | 3.8 | |||
| Methotrexate | 5,676 | 45.1 | — | 2,042 | 40.4 | |||
| Radiotherapy* | ||||||||
| Any radiotherapy | 8,547 | 68.0 | — | 3,709 | 73.4 | |||
| Brain | 4,010 | 32.6 | — | 1,393 | 28.1 | |||
| Chest | 2,467 | 20.1 | — | 1,458 | 29.4 | |||
| Abdomen | 2,200 | 17.9 | — | 1,126 | 22.7 | |||
| Pelvis | 1,863 | 15.2 | — | 887 | 17.9 | |||
| Combinations* | ||||||||
| Chest RT plus bleomycin | 339 | 2.8 | — | 188 | 3.8 | |||
| Chest RT plus abdominal/pelvic RT | 1,435 | 11.7 | — | 851 | 17.2 | |||
| Alkylator plus abdominal/pelvic RT | 1,636 | 13.3 | — | 762 | 15.4 | |||
| Chest RT plus anthracyclines | 966 | 7.9 | — | 395 | 8.0 | |||
| Anthracyclines plus an alkylator | 5,190 | 41.3 | — | 1,841 | 36.5 | |||
Abbreviations: RT, radiotherapy.
*
Percentages calculated on total No. of participants on whom information was available.